Write a review
Reviews: 0
Active ingredients
- Not indicated. See instructions
Disease class
- Not indicated. See instructions
Clinical and pharmacological group
- Not indicated. See instructions
Pharmacological action
- Immunostimulating
- Normalizing vaginal microflora
- Antibacterial
Pharmacological group
- Vaccines, serums, phages and toxoids
Pharmacodynamics and pharmacokinetics
Pharmacodynamics
The use of the vaccine activates specific and nonspecific immunity, regulates the balance of vaginal microflora and prevents the risk of reinfection in case of recurrent vaginal infections.
Under the influence of the vaccine, the level of humoral IgG antibodies to antigens of atypical lactobacilli , and the level of specific sIgA antibodies in vaginal secretions increases. Over time, the content of specific antibodies decreases, but the protective effect remains, which reduces the risk of reinfection. In addition, the use of the vaccine activates polyclonal B-lymphocytes , increases the phagocytic activity of macrophages and T-lymphocytes .
Activation of the body's immunological reactions promotes the growth of Doderlein bacilli , elimination of atypical forms of lactobacilli, restoration of the pH of the vaginal mucosa and normal microflora.
Pharmacokinetics
Pharmacokinetic studies have not been conducted.
Lyophilisate for the preparation of solution for injection SolcoTrichovac (SolcoTrichovac)
Instructions for medical use of the drug
Description of pharmacological action
Vaccination with SolkoTrichovak leads to the activation of specific and nonspecific immunological reactions of the body. Activation of specific immunity The use of SolkoTrichovak leads to an increase in the content of humoral antibodies of the IgG class to the surface antigens of lactobacilli, to an increase in total sIgA, as well as an increase in the level of specific sIgA antibodies in the vaginal secretion. Despite the fact that some time after administration of the drug the content of specific sIgA antibodies decreases to the initial level, the protective effect of the drug, which reduces the risk of re-infection, remains. Activation of nonspecific immunity In experiments in vitro and in vivo, it was shown that the use of SolkoTrichovak activates polyclonal B-lymphocytes and also stimulates the formation of nonspecific antibodies of the IgA class. In vitro experiments examining biological materials obtained from animals vaccinated with SolcoTrichovac revealed a significant short-term increase in the phagocytic activity of macrophages, as well as the cytotoxic activity of T-lymphocytes. Mobilization of specific and nonspecific immunological reactions of the body against the background of vaccination with SolkoTrichovak is directed against the antigens contained in the drug (H2O2-negative strains of lactobacilli), which contributes to the elimination of atypical forms of lactobacilli, the growth of physiological Doderlein bacilli and, as a consequence, the restoration of normal microflora and normalization of the physiological pH value vaginal mucosa. Vaccination with SolkoTrichovak not only stabilizes the vaginal microenvironment, but also prevents the risk of relapse and reinfection in 80% of patients with recurrent vaginal infections.
Indications for use
Prevention and treatment of recurrent nonspecific bacterial vaginosis and recurrent trichomoniasis in women.
Release form
lyophilisate for preparing a suspension for intramuscular administration; bottle (bottle) with solvent in ampoules box (box) 1. lyophilisate for preparing a suspension for intramuscular administration; bottle (bottle) with solvent in ampoules box (box) 3. lyophilisate for preparing a suspension for intramuscular administration; bottle (bottle) 0.5 ml with solvent in ampoules contour plastic packaging (pallets) 1 cardboard pack 1. lyophilisate for preparing a suspension for intramuscular administration; bottle (bottle) 0.5 ml with solvent in ampoules contour plastic packaging (pallets) 3 packs of cardboard 1.
Use during pregnancy
To date, there are no clinical trial data on the use of SolcoTrichovac during pregnancy and breastfeeding, so the use of the drug in these categories of patients is possible if the expected benefit to the mother outweighs the possible risk to the fetus.
Contraindications for use
Hypersensitivity to the components of the drug, acute infectious diseases, acute tuberculosis, diseases of the hematopoietic system (acute leukemia, etc.), heart and kidney diseases with symptoms of decompensation, diseases of the immune system (HIV).
Side effects
Rarely - local reactions in the form of redness, swelling and pain at the injection site. In some cases, general reactions are possible: short-term increase in body temperature (up to 40 °C), chills, headache, fatigue.
Directions for use and doses
V/m. The vaccination course consists of 3 injections in a single dose of 0.5 ml (contents of 1 bottle) with an interval between injections of 2 weeks. The timing of vaccination should be calculated so that the administration of the drug does not coincide with the patient’s menstrual cycle. After 1 year, a single revaccination is carried out at a dose of 0.5 ml. Subsequently, a single revaccination is carried out every 2 years. To prepare a ready-to-use vaccine, the contents of an ampoule with a solvent (0.5 ml of water for injection) are injected into a vial containing a lyophilized drug using a sterile syringe. The lyophilisate dissolves within 30 s. The suspension, ready for use, must be homogeneous. The prepared suspension is used immediately. Before taking the suspension into the syringe, the bottle should be shaken.
Interactions with other drugs
It is not recommended to mix SolkoTrichovak and other parenteral drugs and vaccines in one syringe.
Special instructions for use
In case of acute trichomoniasis, vaccination with SolkoTrichovak should be carried out only after preliminary etiotropic treatment. The drug should not be prescribed for sexually transmitted diseases (gonorrhea, syphilis). The use of the drug in children under 15 years of age is possible in cases of extreme necessity, when the expected therapeutic effect exceeds the risk of developing possible side effects (no clinical trial data are available). During treatment with immunosuppressants and/or during radiation therapy, a partial or complete loss of the effectiveness of SolcoTrichovac may be observed. The drug should not be used if there are cracks on the bottle with lyophilisate or on the ampoule of water for injection, if the labeling is unclear, or if the physical properties of the dissolved drug are violated. The drug does not affect the ability to operate machinery or drive vehicles.
Storage conditions
In a dry place, at a temperature of 15–25 °C.
Best before date
36 months
ATX classification:
J Antimicrobials for systemic use
J07 Vaccines
J07A Vaccines for the prevention of bacterial infections
J07AX Other vaccines for the prevention of bacterial infections
Solcotrichovac, instructions for use (Method and dosage)
The vaccine is administered intramuscularly. The course requires 3 injections of 0.5 ml, which are performed at intervals of 2 weeks. Revaccination is carried out after a year and this provides protection for 2 years. According to indications, revaccinations are carried out every 2 years.
A sterile solvent is introduced into a vial of lyophilized powder. The lyophilisate dissolves within 30 seconds to form a translucent whitish suspension, which is used immediately. Do not use the drug if a crack occurs on the bottle or ampoule.
Release form and composition
Dosage form – lyophilisate for the preparation of an injection suspension, which is a porous tablet of a white, freeze-dried substance; when dissolved in injection water, a translucent matte suspension is formed [1 vaccination dose in bottles, in a box 1 or 3 bottles complete with one or three ampoules with solvent (0.5 ml of water for injection)].
Active substance: inactivated lyophilized microorganisms of the acidophilic lactobacilli strain (Lactobacillus acidophilus), in 1 dose - at least 7x109.
Auxiliary components: phenol (preservative), sodium chloride and repolymerized gelatin (hemacel).
Reviews of Solcotrichovac
For the treatment and prevention of trichomoniasis and bacterial vaginosis, the Solcotrichovac vaccine has been created, which is used as a single drug or as part of complex treatment. The drug helps to increase lactobacilli colonies and stabilize the pH, which creates unfavorable conditions for the proliferation of T. vaginalis. Atypical lactobacilli are suppressed, trichomonas and pathogenic bacterial flora are simultaneously suppressed, conditions are created for the growth of Doderlein bacilli and resistance to reinfection increases. It should be taken into account that the antibody titer increases no earlier than after 2-3 weeks, so women feel symptoms of improvement 14 days after the injection. The vaccine has been proven to be highly effective in the treatment of trichomoniasis and bacterial vaginosis. After its use, the number of relapses significantly decreases. The use of immunization has a number of advantages over the use of antimicrobial drugs: the ability to reduce the dose of drugs and the duration of treatment, and reduce the incidence of side effects (dysbiotic phenomena).
Similar drugs:
- Furacilin Solution for topical use
- Lactobacterin siccum dry (Lactobacterin siccum) Lyophilisate for the preparation of solution for oral administration
- Palin Capsule
- Bactrim Oral suspension
- Nitroxoline Oral tablets
- Pancef Oral tablets
- Nifuroxazide (Nifuroxazide) Oral tablets
- Ercefuryl Oral suspension
- Sextaphag Oral solution
- Pancef Granules for the preparation of suspension for oral administration
** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use the drug SolkoTrichovak, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.
Are you interested in the drug SolkoTrichovak? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.
** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug SolkoTrichovak is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!
If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.
special instructions
Clinical trials on the safety of the vaccine during pregnancy and lactation have not been conducted, so during these periods the drug can be used only in cases where the expected benefits outweigh the potential risks.
Vaccination should not be carried out for sexually transmitted diseases. In the case of acute trichomoniasis, the drug can be administered only after preliminary etiotropic treatment.
For girls under 15 years of age, SolkoTrichovak can be prescribed only in cases of extreme necessity, if the intended therapeutic effect is higher than the risk of developing possible side effects.
SolkoTrichovak should not be administered if: the bottle with the lyophilisate or ampoule with the solvent has cracks, the labeling on the drug is unclear, or the physical properties of the dissolved lyophilisate are impaired.
When carrying out radiation therapy and/or simultaneous use of immunosuppressants, partial or complete loss of vaccine effectiveness is possible.
The drug does not affect the speed of reactions and the ability to concentrate.
